company background image
PAB

PatrysASX:PAB Stock Report

Market Cap

AU$78.6m

7D

0%

1Y

95.5%

Updated

16 Oct, 2021

Data

Company Financials
PAB fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

PAB Overview

Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia.

Price History & Performance

Summary of all time highs, changes and price drops for Patrys
Historical stock prices
Current Share PriceAU$0.043
52 Week HighAU$0.017
52 Week LowAU$0.063
Beta-0.54
1 Month Change7.50%
3 Month Change-15.69%
1 Year Change95.46%
3 Year Change13.16%
5 Year Change514.29%
Change since IPO-93.23%

Recent News & Updates

Sep 28
We're Not Very Worried About Patrys' (ASX:PAB) Cash Burn Rate

We're Not Very Worried About Patrys' (ASX:PAB) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Patrys ( ASX:PAB...

Shareholder Returns

PABAU BiotechsAU Market
7D0%2.3%0.9%
1Y95.5%1.5%20.2%

Return vs Industry: PAB exceeded the Australian Biotechs industry which returned 1.5% over the past year.

Return vs Market: PAB exceeded the Australian Market which returned 20.2% over the past year.

Price Volatility

Is PAB's price volatile compared to industry and market?
PAB volatility
PAB Beta-0.54
Industry Beta1.61
Market Beta1

Stable Share Price: PAB is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: PAB's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
2006n/aJames Campbellhttps://www.patrys.com

Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. Its lead technology is Deoxymab 3E10, a DNA damage-repair antibody that penetrates cell nuclei and inhibits mechanisms of DNA repair in target cancer cells. The company also focuses on developing PAT-DX1, an antibody fragment for the treatment of primary and secondary brain cancer, triple negative breast cancer, and glioblastoma.

Patrys Fundamentals Summary

How do Patrys's earnings and revenue compare to its market cap?
PAB fundamental statistics
Market CapAU$78.61m
Earnings (TTM)-AU$4.06m
Revenue (TTM)AU$1.34m

58.9x

P/S Ratio

-19.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PAB income statement (TTM)
RevenueAU$1.34m
Cost of RevenueAU$0
Gross ProfitAU$1.34m
ExpensesAU$5.40m
Earnings-AU$4.06m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.0022
Gross Margin100.00%
Net Profit Margin-303.57%
Debt/Equity Ratio0.0%

How did PAB perform over the long term?

See historical performance and comparison

Valuation

Is Patrys undervalued compared to its fair value and its price relative to the market?

6.53x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate PAB's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate PAB's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: PAB is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.

PE vs Market: PAB is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PAB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PAB is overvalued based on its PB Ratio (6.5x) compared to the AU Biotechs industry average (4.9x).


Future Growth

How is Patrys forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

11.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Patrys has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Patrys performed over the past 5 years?

-27.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PAB is currently unprofitable.

Growing Profit Margin: PAB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PAB is unprofitable, and losses have increased over the past 5 years at a rate of 27.4% per year.

Accelerating Growth: Unable to compare PAB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PAB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (45.9%).


Return on Equity

High ROE: PAB has a negative Return on Equity (-33.74%), as it is currently unprofitable.


Financial Health

How is Patrys's financial position?


Financial Position Analysis

Short Term Liabilities: PAB's short term assets (A$12.4M) exceed its short term liabilities (A$849.9K).

Long Term Liabilities: PAB has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: PAB is debt free.

Reducing Debt: PAB has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PAB has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: PAB has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 6% each year.


Dividend

What is Patrys's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PAB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PAB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PAB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PAB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PAB's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.8yrs

Average board tenure


CEO

James Campbell

6.5yrs

Tenure

AU$601,202

Compensation

Dr. James A. Campbell, BSc(Hons), PhD, MBA, GAICD, serves as Chief Executive Officer and Managing Director for Patrys Limited since April 13, 2015. Dr. Campbell serves as Principal of Gemini Biotechnology....


CEO Compensation Analysis

Compensation vs Market: James's total compensation ($USD446.23K) is above average for companies of similar size in the Australian market ($USD302.45K).

Compensation vs Earnings: James's compensation has increased whilst the company is unprofitable.


Board Members

Experienced Board: PAB's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27.4%.


Top Shareholders

Company Information

Patrys Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Patrys Limited
  • Ticker: PAB
  • Exchange: ASX
  • Founded: 2006
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$78.612m
  • Shares outstanding: 1.83b
  • Website: https://www.patrys.com

Location

  • Patrys Limited
  • 100 Albert Road
  • Level 4
  • Melbourne
  • Victoria
  • 3205
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/16 07:04
End of Day Share Price2021/10/15 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.